Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

View CSAF
Summary
Successful exploitation of these vulnerabilities could allow an attacker to obtain sensitive health-related information and prevent legitimate users from establishing a connection with the device.
The following versions of Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT are affected:

Blood Glucose Monitoring System (Model No. APG-01 BT) 0x0110_v1.1.0 (CVE-2026-50034, CVE-2026-52866)





CVSS
Vendor
Equipment
Vulnerabilities




v3 6.5
Apollo Pharmacy
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT
Cleartext Transmission of Sensitive Information, Missing Authorization




Background

Critical Infrastructure Sectors: Healthcare and Public Health
Countries/Areas Deployed: India
Company Headquarters Location: India


Vulnerabilities

Expand All +

CVE-2026-50034

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.
View CVE Details

Affected Products
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

Vendor:Apollo Pharmacy
Product Version:Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT): 0x0110_v1.1.0
Product Status:known_affected


Remediations
MitigationApollo Pharmacy did not respond to CISA's requests to coordinate. Users are encouraged to reach out to Apollo Pharmacy directly for more information:https://www.apollopharmacy.in/contact-us.https://www.apollopharmacy.in/contact-us
MitigationCISA recommends users follow the guidance in the Understanding Bluetooth Technology blog https://www.cisa.gov/news-events/news/understanding-bluetooth-technology.https://www.cisa.gov/news-events/news/understanding-bluetooth-technology

Relevant CWE: CWE-319 Cleartext Transmission of Sensitive Information

Metrics




CVSS Version
Base Score
Base Severity
Vector String




3.1
6.5
MEDIUM
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N


4.0
7.1
HIGH
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N







CVE-2026-52866

An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
View CVE Details

Affected Products
Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

Vendor:Apollo Pharmacy
Product Version:Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT): 0x0110_v1.1.0
Product Status:known_affected


Remediations
MitigationApollo Pharmacy did not respond to CISA's requests to coordinate. Users are encouraged to reach out to Apollo Pharmacy directly for more information:https://www.apollopharmacy.in/contact-us.https://www.apollopharmacy.in/contact-us
MitigationCISA recommends users follow the guidance in the Understanding Bluetooth Technology blog https://www.cisa.gov/news-events/news/understanding-bluetooth-technology.https://www.cisa.gov/news-events/news/understanding-bluetooth-technology

Relevant CWE: CWE-862 Missing Authorization

Metrics




CVSS Version
Base Score
Base Severity
Vector String




3.1
6.5
MEDIUM
CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H


4.0
7.1
HIGH
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N








Acknowledgments

Rishitha Pucchakayala and Centre for Development of Advanced Computing (Hyderabad) reported these vulnerabilities to CISA


Legal Notice and Terms of Use
This product is provided subject to this Notification (https://www.cisa.gov/notification) and this Privacy & Use policy (https://www.cisa.gov/privacy-policy).

Recommended Practices
CISA recommends users take defensive measures to minimize the risk of exploitation of these vulnerabilities.
Minimize network exposure for all control system devices and/or systems, ensuring they are not accessible from the internet.
Locate control system networks and remote devices behind firewalls and isolating them from business networks.
When remote access is required, use more secure methods, such as Virtual Private Networks (VPNs), recognizing VPNs may have vulnerabilities and should be updated to the most current version available. Also recognize VPN is only as secure as the connected devices.
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage on cisa.gov/ics. Several CISA products detailing cyber defense best practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
CISA encourages organizations to implement recommended cybersecurity strategies for proactive defense of ICS assets.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage at cisa.gov/ics in the technical information paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing suspected malicious activity should follow established internal procedures and report findings to CISA for tracking and correlation against other incidents.
No known public exploitation specifically targeting these vulnerabilities has been reported to CISA at this time. These vulnerabilities are not exploitable remotely.

Revision History

Initial Release Date: 2026-06-18




Date
Revision
Summary




2026-06-18
1
Initial Publication




Legal Notice and Terms of Use

https://www.cisa.gov/news-events/ics-medical-advisories/icsma-26-169-01

2026-06-18 12:00 UTC
--- FMail-lnx 2.3.4.1-B20260522
* Origin: TCOB1 A Mail Only System (2:263/1)